Skip to content

Study · Randomized controlled trial · 2016

4 results

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.

Mader JK, Jensen L, Ingwersen SH, Christiansen E, Heller S, Pieber TR

Clinical pharmacokinetics1 Nov 2016Cited by 10 (Europe PMC)

PMID27282158 (opens in a new tab)PMCIDPMC5069309 (opens in a new tab)DOI10.1007/s40262-016-0413-4 (opens in a new tab)PepBankPUB-27282158
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In adults with type 1 diabetes on insulin, liraglutide pharmacokinetics were comparable with those in healthy volunteers and subjects with T2D.

    In plain wordsIn adults with type 1 diabetes using insulin, liraglutide behaved in the body like it does in healthy people and people with type 2 diabetes.

    Peptide
    Liraglutide
    Outcome
    No significant changePharmacokinetic properties in T1D versus healthy volunteers and T2D
    Study

    n: not reported in source

    Comparator
    Healthy volunteers and subjects with T2D from previous trials
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.6, 1.2 or 1.8 mg · subcutaneous · 4 weeks per treatment periodAs given in this study (human).

    Source sentences

    Summary
    The pharmacokinetic properties of liraglutide in T1D were comparable with those observed in healthy volunteers and subjects with T2D.
    2 context sentences
    Summary · context
    Subjects (18-64 years; body mass index 20.0-28.0 kg/m2; glycated hemoglobin ≤9.5 %) were randomized 1:1:1 to 0.6, 1.2, or 1.8 mg liraglutide/placebo.
    Summary · context
    Each group underwent two 4-week treatment periods (liraglutide then placebo or placebo then liraglutide) separated by a 2- to 3-week washout.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In adults with type 1 diabetes on insulin, steady-state AUC of liraglutide was consistent with dose proportionality.

    In plain wordsIn adults with type 1 diabetes using insulin, total liraglutide exposure rose in proportion to the dose.

    Peptide
    Liraglutide
    Outcome
    Not applicableDose proportionality of AUC
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.6, 1.2 or 1.8 mg · subcutaneous · 4 weeks per treatment periodAs given in this study (human).

    Source sentences

    Summary
    Area under the steady-state concentration-time curve (AUC) and maximum plasma concentration data were consistent with dose proportionality of liraglutide.
    2 context sentences
    Summary · context
    Subjects (18-64 years; body mass index 20.0-28.0 kg/m2; glycated hemoglobin ≤9.5 %) were randomized 1:1:1 to 0.6, 1.2, or 1.8 mg liraglutide/placebo.
    Summary · context
    Each group underwent two 4-week treatment periods (liraglutide then placebo or placebo then liraglutide) separated by a 2- to 3-week washout.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In adults with type 1 diabetes on insulin, maximum plasma concentration of liraglutide was consistent with dose proportionality.

    In plain wordsIn adults with type 1 diabetes using insulin, peak liraglutide level rose in proportion to the dose.

    Peptide
    Liraglutide
    Outcome
    Not applicableDose proportionality of maximum plasma concentration
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.6, 1.2 or 1.8 mg · subcutaneous · 4 weeks per treatment periodAs given in this study (human).

    Source sentences

    Summary
    Area under the steady-state concentration-time curve (AUC) and maximum plasma concentration data were consistent with dose proportionality of liraglutide.
    2 context sentences
    Summary · context
    Subjects (18-64 years; body mass index 20.0-28.0 kg/m2; glycated hemoglobin ≤9.5 %) were randomized 1:1:1 to 0.6, 1.2, or 1.8 mg liraglutide/placebo.
    Summary · context
    Each group underwent two 4-week treatment periods (liraglutide then placebo or placebo then liraglutide) separated by a 2- to 3-week washout.
  4. 04HumanRandomized controlled trialPharmacokinetics

    In adults with type 1 diabetes given liraglutide with insulin, dose-normalized AUC was comparable with that in T2D.

    In plain wordsIn adults with type 1 diabetes using insulin, liraglutide exposure was similar to that in people with type 2 diabetes.

    Peptide
    Liraglutide
    Outcome
    No significant changeDose-normalized AUC in T1D versus T2D
    Study

    n: not reported in source

    Comparator
    Subjects with T2D from previous trials
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.6, 1.2 or 1.8 mg · subcutaneous · 4 weeks per treatment periodAs given in this study (human).

    Source sentences

    Summary
    Comparison of dose-normalized liraglutide AUC suggested that exposure in T1D, when administered with insulin, is comparable with that observed in T2D.
    2 context sentences
    Summary · context
    Subjects (18-64 years; body mass index 20.0-28.0 kg/m2; glycated hemoglobin ≤9.5 %) were randomized 1:1:1 to 0.6, 1.2, or 1.8 mg liraglutide/placebo.
    Summary · context
    Each group underwent two 4-week treatment periods (liraglutide then placebo or placebo then liraglutide) separated by a 2- to 3-week washout.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01536665

The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes

Novo Nordisk A/Sn = 45Feb 2012 to Aug 2012

Diabetes · Diabetes Mellitus, Type 1

Trial pageClinicalTrials.govUpdated 8 Feb 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.